{"log_id": 5517897745359719324, "direction": 0, "words_result_num": 29, "words_result": [{"probability": {"variance": 0.013367, "average": 0.962872, "min": 0.448601}, "location": {"width": 931, "top": 154, "height": 40, "left": 152}, "words": "水潴留可以加重或导致心衰,目前尚无严重心衰患者(按纽约心脏学会分类法的ⅢII~Ⅳ级)"}, {"probability": {"variance": 2e-06, "average": 0.99921, "min": 0.993511}, "location": {"width": 971, "top": 204, "height": 38, "left": 104}, "words": "临床应用甲磺酸伊马替尼的经验,有心脏病、心力衰竭风险因素或肾衰竭病史的患者,需进"}, {"probability": {"variance": 4e-05, "average": 0.997756, "min": 0.961658}, "location": {"width": 969, "top": 254, "height": 36, "left": 105}, "words": "行密切监测;对任何有心力衰竭或肾衰竭体征或症状的患者要进行评价与治疗;青光眼的患"}, {"probability": {"variance": 8.7e-05, "average": 0.995393, "min": 0.96422}, "location": {"width": 318, "top": 304, "height": 32, "left": 106}, "words": "者也应慎用(见【不良反应】)。"}, {"probability": {"variance": 0.0003, "average": 0.992855, "min": 0.916878}, "location": {"width": 898, "top": 350, "height": 36, "left": 154}, "words": "已证实某些嗜酸性粒细胞增多综合征(HES)伴有心肌组织内HES细胞隐性浸润的患者"}, {"probability": {"variance": 0.001787, "average": 0.9918, "min": 0.729113}, "location": {"width": 945, "top": 398, "height": 35, "left": 107}, "words": "出现心源性休克/左心室功能紊乱与使用伊马替尼时出现的HES细胞脱颗粒有关。据报道"}, {"probability": {"variance": 4e-06, "average": 0.998916, "min": 0.98953}, "location": {"width": 965, "top": 447, "height": 31, "left": 109}, "words": "可以通过全身使用类固醇激素、循环支持治疗和暂时停用伊马替尼使病情改善。骨髓增生异"}, {"probability": {"variance": 8e-06, "average": 0.998541, "min": 0.985138}, "location": {"width": 968, "top": 496, "height": 30, "left": 107}, "words": "常/骨髓增生性疾病及系统性肥大细胞增生症可能与高嗜酸性粒细胞浓度有关。因此应考虑对"}, {"probability": {"variance": 0.005494, "average": 0.982823, "min": 0.627888}, "location": {"width": 965, "top": 543, "height": 31, "left": 108}, "words": "HES/CEL的患者,MDS/MPD或高嗜酸性粒细胞引起SM的患者进行超声心动图检查及血清"}, {"probability": {"variance": 0.000419, "average": 0.994633, "min": 0.879538}, "location": {"width": 964, "top": 590, "height": 33, "left": 106}, "words": "肌钙蛋白的测定。如果出现任何一项测量结果异常,应预防性的使用全身类固醇治疗(1~"}, {"probability": {"variance": 0.00196, "average": 0.988719, "min": 0.773949}, "location": {"width": 497, "top": 639, "height": 31, "left": 109}, "words": "2mg/kg)1~2周,并同时使用伊马替尼进行治疗"}, {"probability": {"variance": 0.000334, "average": 0.994196, "min": 0.886581}, "location": {"width": 921, "top": 687, "height": 30, "left": 155}, "words": "在GIST临床试验中,报告有8例患者(5.4%)出现胃肠道出血和4例患者(2.7%)出"}, {"probability": {"variance": 2.3e-05, "average": 0.998472, "min": 0.970188}, "location": {"width": 946, "top": 735, "height": 31, "left": 106}, "words": "现肿瘤内出血。根据肿瘤的部位不同,肿瘤内出血可能发生在腹腔内,也可能发生在肝内"}, {"probability": {"variance": 1e-06, "average": 0.99938, "min": 0.992578}, "location": {"width": 969, "top": 782, "height": 33, "left": 107}, "words": "这类患者的肿瘤内出血也有可能表现为胃肠道出血,因此,在治疗开始阶段应监测患者的胃"}, {"probability": {"variance": 1e-06, "average": 0.998924, "min": 0.997069}, "location": {"width": 96, "top": 835, "height": 27, "left": 109}, "words": "肠道症状"}, {"probability": {"variance": 7e-06, "average": 0.997703, "min": 0.991951}, "location": {"width": 173, "top": 883, "height": 29, "left": 106}, "words": "肿瘤溶解综合征"}, {"probability": {"variance": 0.000115, "average": 0.996545, "min": 0.937119}, "location": {"width": 911, "top": 926, "height": 34, "left": 157}, "words": "使用伊马替尼治疗的患者已报告有肿瘤溶解综合征(TLS)的病例。鉴于可能发生TLS"}, {"probability": {"variance": 0, "average": 0.99962, "min": 0.997773}, "location": {"width": 869, "top": 973, "height": 36, "left": 109}, "words": "建议在使用伊马替尼治疗前,纠正临床上显著的脱水情况并对高尿酸水平进行治疗"}, {"probability": {"variance": 0, "average": 0.99944, "min": 0.998415}, "location": {"width": 121, "top": 1028, "height": 28, "left": 110}, "words": "实验室检查"}, {"probability": {"variance": 3.2e-05, "average": 0.997512, "min": 0.969917}, "location": {"width": 921, "top": 1070, "height": 34, "left": 157}, "words": "本品治疗期间应定期进行全血细胞计数检查。接受本品治疗的CML患者常伴发中性粒"}, {"probability": {"variance": 1e-06, "average": 0.999333, "min": 0.994801}, "location": {"width": 778, "top": 1116, "height": 37, "left": 109}, "words": "细胞减少症或血小板减少症。然而血细胞减少症的发生也取决于疾病分期"}, {"probability": {"variance": 8.7e-05, "average": 0.997061, "min": 0.941103}, "location": {"width": 929, "top": 1163, "height": 39, "left": 110}, "words": "患者相比,加速期CML或急变期更常见。此时应中断本品治疗或减量,见【用法用量】。"}, {"probability": {"variance": 3.4e-05, "average": 0.997558, "min": 0.965053}, "location": {"width": 919, "top": 1212, "height": 36, "left": 155}, "words": "接受本品治疗的患者应定期监测肝功能(转氨酶、胆红素、碱性磷酸酶)。见【用法用量】"}, {"probability": {"variance": 0.000623, "average": 0.992486, "min": 0.902536}, "location": {"width": 322, "top": 1265, "height": 32, "left": 110}, "words": "若出现异常即应中断和/或减量"}, {"probability": {"variance": 1.7e-05, "average": 0.998146, "min": 0.983189}, "location": {"width": 919, "top": 1310, "height": 32, "left": 160}, "words": "本品及其代谢产物几乎不通过肾脏排泄。肌酐清除率(CrCL)随着年龄的增长而下降,但"}, {"probability": {"variance": 6e-06, "average": 0.998851, "min": 0.984205}, "location": {"width": 968, "top": 1358, "height": 32, "left": 112}, "words": "年龄对本品的药代动力学无显著影响。肾功能不全患者的伊马替尼血浆暴露量似乎高于肾功"}, {"probability": {"variance": 0.000767, "average": 0.993177, "min": 0.851511}, "location": {"width": 966, "top": 1405, "height": 34, "left": 112}, "words": "能正常的患者,可能是由于这些患者的血浆中a酸性糖蛋白(AGP)-种伊马替尼结合蛋白"}, {"probability": {"variance": 8e-06, "average": 0.999214, "min": 0.982163}, "location": {"width": 961, "top": 1451, "height": 37, "left": 118}, "words": "水平增高所致。伊马替尼的血浆暴露量与按肌酐清除率评价的肾功能不全无相关性,即与轻"}, {"probability": {"variance": 0.002835, "average": 0.98271, "min": 0.640934}, "location": {"width": 968, "top": 1500, "height": 35, "left": 111}, "words": "度(CrCL:40~59m/min)和重度(CrCL:<20ml/min)肾功能不全无相关性。然而,正如【用"}], "language": 3}